Clinical Scorecard: Exploring the Connection Between Renal Function and Neurodegenerative Disorders
At a Glance
Category
Detail
Condition
Chronic kidney disease (CKD) and neurodegenerative diseases including dementia, Alzheimer's disease (AD), and Parkinson's disease (PD)
Key Mechanisms
Shared vascular risk factors, neuroinflammation, oxidative stress, accumulation of pathological proteins, and genetic links
Target Population
Adults and elderly populations, including those with CKD, dementia, AD, and PD
Care Setting
Primary care, nephrology, neurology, geriatrics, and specialized dementia care settings
Key Highlights
CKD affects approximately 11%–13% of the general population and up to 40% of individuals over 60 years old.
CKD is associated with increased risk of cognitive impairment and is prevalent in 30%–60% of persons living with dementia.
Alzheimer’s disease and Parkinson’s disease share common risk factors with CKD, including hypertension, diabetes, and vascular dysfunction.
Guideline-Based Recommendations
Diagnosis
Diagnose CKD using estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 for over 3 months or urinary albumin-to-creatinine ratio (uACR) >30 mg/g.
Assess cognitive impairment and dementia through clinical evaluation, considering overlapping risk factors with CKD.
Management
Manage vascular risk factors such as hypertension, diabetes, and hyperlipidaemia to potentially reduce risks for both CKD progression and neurodegeneration.
Consider multidisciplinary approaches targeting kidney health as a potential avenue to improve or delay cognitive decline.
Monitoring & Follow-up
Regularly monitor kidney function (eGFR, uACR) in patients with neurodegenerative diseases.
Monitor cognitive function in patients with CKD, especially those undergoing dialysis or with advanced disease.
Risks
Increased mortality associated with CKD and dementia, with overlapping risk factors exacerbating disease progression.
Potential for more severe cognitive and neuropsychiatric symptoms in PD patients with renal insufficiency.
Patient & Prescribing Data
Adults and elderly patients with CKD and/or neurodegenerative diseases such as AD and PD
Current evidence suggests targeting vascular and metabolic risk factors may benefit both kidney and brain health; however, specific pharmacological interventions linking renal and neurodegenerative disease treatment require further research.
Clinical Best Practices
Screen for cognitive impairment in patients with CKD, especially older adults and those on dialysis.
Address modifiable vascular risk factors aggressively to reduce risks of both CKD progression and neurodegeneration.
Adopt a multidisciplinary care model involving nephrologists, neurologists, and primary care providers to optimize patient outcomes.
Encourage further research into mechanistic and genetic links between kidney function and neurodegenerative diseases to inform future therapeutic strategies.
Diagnosing Parkinson’s disease has long depended primarily on clinical expertise — careful neurologic examination, longitudinal symptom assessment and the nuanced interpretation of movement abnormalities.
